GM PHARMA

What GM PHARMA does

GM PHARMA (LLC "GM Pharmaceuticals") is a privately held, Georgia-domiciled international pharmaceutical manufacturer founded in 1997, following the post-Soviet pharmaceutical shortages that motivated the creation of a domestic GMP-compliant industry. The company operates the largest pharmaceutical manufacturing plant in the Caucasus region from its headquarters in Tbilisi (N52 Rustavi Highway), running a full-cycle solid-dosage production line — blending, granulation, tableting, coating, capsule/sachet/bottle filling, blister and bottle packaging — on Tier-1 Western European equipment from suppliers including Gerteis, L.B. Bohle, Bosch, Fette, Ima, Uhlmann, Korsch, Glatt, Sartorius, Mettler Toledo and Waters. A dedicated R&D laboratory established in 2018 covers Process Development (Technological) and Analytical Development, with 20+ new products under development including fixed-dose combinations and polypills. The product portfolio spans 12 therapeutic areas — allergology, anti-infectives, antithrombotics, cardiovascular, cold & flu, gastroenterology, gynecology, NSAID, respiratory, urology, venotonics, and vitamins/food supplements — across RX, OTC, food supplement, and medical device categories.

The commercial model combines proprietary branded generics distributed through pharmacy networks in Georgia and seven export countries (Uzbekistan, Tajikistan, Kyrgyzstan, Armenia, Moldova, Azerbaijan, Kazakhstan) served by 250+ field-force employees across 7 representative offices, with contract-manufacturing arrangements for Western European partners including Idee PharmaWelt, Kern Pharma, Laboratórios BASI, Menarini, Laboratorios Cinfa, Erbozeta, Lallemand, Bago Laboratories, Reig Jofre and Combino Pharm. The regulatory footprint is unusually broad for a Caucasus-domiciled manufacturer: Georgian national GMP, EU GMP (EudraLex Vol. 4, audited by Germany's Heacon Service GmbH in 2023), PIC/S GMP, ISO 9001:2015, ISO 17025:2017/2018, NSF/ANSI dietary supplement certification, EAEU GMP, plus country-specific GMP clearances from Uzbekistan and Azerbaijan. The company states it treats up to 14 million patients annually, ranks top-5 among foreign pharma companies by value sold in Uzbekistan, and aspires to enter the global top-200 pharma list with $1B in export value. Pricing is not publicly disclosed.

Name

GM PHARMA

Legal name

LLC "GM Pharmaceuticals"

Website

https://gmpharma.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

GM PHARMA is a Georgia-founded pharmaceutical manufacturer operating the Caucasus' largest solid-dosage plant, producing branded generics, food supplements and medical devices across 12 therapeutic areas for patients in Georgia and seven export countries in the post-Soviet corridor, supplemented by Western European co-manufacturing partnerships.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Contract manufacturing
• Active pharmaceutical ingredients
• Branded generics

Headquarters

HQ city

Tbilisi

HQ country

Georgia

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical products and biologics: Sale of prescription (RX), over-the-counter (OTC), food supplements (FS), and medical devices (MD). The company manufactures and distributes medicines and biologically active food supplements through GMP-certified plants in Western European countries and its own GMP-certified plant in Georgia, serving patients in Georgia and international export markets.
2. Manufacturing services: Co-manufacturing arrangements with international pharmaceutical partners including Idee PharmaWelt GmbH, Kern Pharma, Laboratórios BASI, Menarini, Laboratorios Cinfa, Erbozeta, Lallemand, Bago Laboratories, Reig Jofre, and Combino Pharm for joint manufacturing operations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

GM PHARMA LLC is an international pharmaceutical manufacturer that develops, produces, and markets branded generic medicines and biologically active food supplements across 12 therapeutic categories from its GMP-certified facility in Tbilisi, Georgia. The company sells its own branded portfolio (Amoxipen, Cardesa, Enap, Cytan, etc.) to wholesale distributors and pharmacies, exports finished products to 7+ countries, and operates co-manufacturing/contract-manufacturing partnerships with Western European pharmaceutical companies that supply the concentrate.

Product overview

GM PHARMA is an international pharmaceutical company that manufactures and distributes medicines and biologically active food supplements. The company's product portfolio includes pharmaceutical products across multiple therapeutic areas (Allergology, Anti-Infectives, Antithrombotic Agents, Cardiovascular Disease, Cold & Flu, Gastroenterology, Gynecology, NSAID, Respiratory, Urology, Venotonics) as well as vitamins and food supplements. Products are manufactured both in the company's own GMP-certified facility in Georgia and through partnerships with Western European manufacturers. The product line includes branded medications such as ALERTEC, LORANEX, AMPIBACT, AZIMAC, MICOFLU, RIVAROX, ADIPIN, AMRADIPIN, EMCOR, TORVITIN, DIALAC, LACTO-G, KLINIZOL, DIOXAFLEX, TENICAM, DOXAFIN, ISMIGEN, EROGRA, TURBO GEL, TURBOMICRON G, as well as vitamin and supplement products including DETRIVIT (Vitamin D3 formulations), OMESAM (Omega-3 and combination products), and ZINCOVID products.

Differentiator

Problem solved

Functional benefit

Products and services

• AMOXIPEN / AMOXIPEN FORTE / MULTIBACTAM (amoxicillin capsules & tablets) Branded generic amoxicillin antibacterial products in capsule and tablet dosage forms intended for the treatment of bacterial infections; sold through pharmacies and wholesale distributors.
• AZIMAC / AZIMAC FORTE (azithromycin) Branded generic azithromycin antibacterial capsules/tablets used to treat a range of bacterial infections; marketed to pharmacy and wholesale channels.
• AKSEF (cefuroxime axetil) Branded generic cefuroxime axetil oral antibacterial (cephalosporin) for the treatment of susceptible bacterial infections; targeted at pharmacies and medical institutions.
• CEFAZIDIME / CEFTRIAXONE / MERONEM (injectable antibacterials) Sterile injectable antibiotics (ceftazidime, ceftriaxone, meropenem) for hospital use in serious bacterial infections; supplied through medical institutions and tender channels.
• FLUCONAZOLE / DIFLUCAN competitor (antifungals) Branded generic oral antifungal capsules for systemic and superficial fungal infections; distributed via pharmacies and wholesale channels.
• CARDESA-AML / CARDESA-AT / CARDESA-H / CARDESA-D / CARDESA Plus (cardiology range) Fixed-dose combination cardiovascular medicines (amlodipine- and atenolol-based combinations; lisinopril/HCTZ; etc.) for hypertension and related cardiovascular conditions; marketed to pharmacies, cardiologists, and wholesale distributors.
• ENAP-A / ENAP-K / ENAP-HL (enalapril combinations) ACE-inhibitor-based combination tablets for hypertension and heart failure; branded generics sold through pharmacy and wholesale channels.
• RAMIPRIL / LISINOPRIL / AMLODIPINE / IRBESARTAN / TELMISARTAN (monocomponent cardiology range) Single-agent cardiovascular tablets (ACE inhibitors, ARBs, calcium channel blockers) for hypertension and cardiovascular risk management; supplied to pharmacies and cardiology practices.
• LORTANOVA / CARDOVAZINE (co-manufactured cardiology products) Cardiovascular tablet products produced by GM PHARMA under contract-manufacturing arrangements with Western European pharmaceutical partners for distribution under partner brands.
• CYTAN / IBUPROFEN / DICLOFENAC / KETANOV / KETOROLAC (NSAID / analgesic range) Branded generic NSAIDs and non-opioid analgesics (ibuprofen, diclofenac, ketorolac/ketanov) for pain, inflammation, and fever; supplied through pharmacy distribution.
• SPASMALGON / ANALGIN / ACETAMINOPHEN / ASPIRIN / NUROFEN competitor (analgesic range) Over-the-counter branded generic analgesics, antipyretics and spasmolytics for pain, fever, and smooth-muscle spasm; sold through pharmacies as consumer healthcare products.
• OMEPRES / OMEPRAZOLE / ESOMEPRAZOLE / PANTAZOL (PPIs) Branded generic proton-pump inhibitor capsules/tablets (omeprazole, esomeprazole, pantoprazole) for acid-related gastrointestinal disorders (GERD, ulcer disease); distributed via pharmacy channels.
• RANITIDINE / LOPERAMIDE / METOCLOPRAMIDE (GI range) Branded generic gastrointestinal medicines (H2 antagonist, antidiarrheal, antiemetic/prokinetic) for gastric, intestinal, and motility disorders; supplied through wholesale and pharmacy distribution.
• ALERTEC / DICETIN (cetirizine), LORATADINE (antihistamine range) Second-generation antihistamine tablets for allergic rhinitis, urticaria, and other allergic conditions; OTC products distributed through pharmacies.
• C-VITAMIN / MULTIVITAMIN (vitamin range) Branded vitamin and multivitamin preparations marketed as dietary supplements and supportive therapy; sold through pharmacies and retail.
• Biologically Active Food Supplements / nutraceutical line Biologically active food supplements and nutraceutical products (e.g., Valeria, Lactovit, Cardiofit) for general health support and disease prevention; sold through pharmacy and retail channels.
• Rifampicin (first manufactured product) Anti-tuberculosis antibacterial capsule — GM PHARMA's inaugural manufactured product, launched in February 2000 and supplied to the Georgian state tuberculosis program and broader market.
• Contract / Co-manufacturing Services for European pharmaceutical partners (e.g., LIVIAL, BROMHEXINE, CARDIOVAZIN, STUGERON under partner brands) B2B contract manufacturing service in which GM PHARMA receives concentrate or specifications from a Western European pharmaceutical partner, performs formulation, quality control, and packaging at its GMP-certified Tbilisi facility, and ships the finished product back to the partner for sale under its own brand in regulated markets.

Quantifiable outcome

• 14 million patients treated annually
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core.

• Idee PharmaWelt GmbHcoreStrategic or Co-development PartnerGlobal manufacturing partner. Address: Westhafenstraße 1, 13353 Berlin, Germany. Partnership involves co-manufacturing of pharmaceutical products including Turbo Gel (Germany-made).
• Kern Pharma, S.LcoreStrategic or Co-development PartnerManufacturing partner. Address: Venus, 72, Pol. Ind. Colom II, 08228 Terrassa, Barcelona. Co-manufactures products such as Turbomicron G tablets.
• Laboratórios BASI-Indústria Farmacêutica, S.AcoreStrategic or Co-development PartnerPortuguese pharmaceutical manufacturing partner. Address: Parque Industrial Manuel Lourenço Ferreira Lote 15, 3450-232 Mortágua, Portugal.
• Menarini Sağlık ve ilaç Sanayi Ticaret A.Ş.coreStrategic or Co-development PartnerTurkish pharmaceutical company. Address: Maltepe, Davutpaşa Cd. No:12, 34010 Zeytinburnu/İstanbul, Turkey. Listed as a global manufacturing partner.
• Laboratorios Cinfa S.A.coreStrategic or Co-development PartnerSpanish pharmaceutical manufacturer. Address: Travesía de Roncesvalles, 31699 Polígono de Olloki, Navarra, Spain.
• Erbozeta S.P.A.coreStrategic or Co-development PartnerSan Marino-based pharmaceutical company. Address: 41/43 Str. Seriole, Repubblica di San Marino, Sm 47890. Manufactures Lacto-G Kids vials.
• Lallemand Inc.coreStrategic or Co-development PartnerSwiss pharmaceutical/biotechnology company. Address: Via Selva 2, 6900 Massagno, Switzerland. Manufactures Ismigen bacterial lysate tablets.
• Bago Laboratories Pte Ltd.coreStrategic or Co-development PartnerArgentine pharmaceutical company. Address: Bernardo de Irigoyen 248 (C1072AAF) CABA, Argentina. Manufactures Dioxaflex B12 injection.
• Reig Jofre Investments S.LcoreStrategic or Co-development PartnerSpanish pharmaceutical company. Address: Carrer del Gran Capità, 6, 08970 Sant Joan Despí, Barcelona, España. Listed as a global partner.
• Combino Pharm (Malta) Ltd.coreStrategic or Co-development PartnerMalta-based pharmaceutical manufacturer. Address: HF 60, Hal Far Industrial Estate, Hal Far Birzebbuga, BBG 3000 Malta. Manufactures Rivarox products.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Polpharma: One of the largest pharmaceutical manufacturers in CEE, producing generics across cardiovascular, anti-infective and other therapeutic areas. Comparable in its integrated manufacturing-plus-distribution model, but with deeper EU market penetration than GM PHARMA.
• Stada Arzneimittel: Germany-headquartered global generics and consumer health leader with strong presence across European and CIS markets. Provides a comparable generics-driven, multi-market distribution business model, though at vastly larger scale and with broader portfolio.
• Gedeon Richter: Hungary-headquartered pharmaceutical company producing generics and specialty drugs across CEE, CIS and Western Europe. Comparable in its integrated manufacturing-plus-export model and geographic focus on CIS markets, though with a larger proprietary/specialty drug portfolio.
• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with significant operations across CEE, CIS and emerging markets. Comparable in its generics manufacturing and broad therapeutic area coverage, though Teva operates at vastly greater scale and includes specialty/innovative drugs.

Direct peers

• Aversi Pharma: Georgian pharmaceutical company and one of GM PHARMA's principal direct competitors in the Caucasus. Operates manufacturing and distribution of generics and OTC products in Georgia and neighboring CIS markets, sharing GM PHARMA's therapeutic breadth and regional distribution footprint.
• PSP (Pharmaceutical Company PSP): Georgian pharmaceutical manufacturer and distributor sharing GM PHARMA's home market. Sells across similar therapeutic categories and distributes through overlapping pharmacy networks in the Caucasus and CIS region, making it one of GM PHARMA's closest direct competitors.

Emerging players

• Krka: Slovenian-headquartered generic pharmaceutical manufacturer with a strong emerging-markets focus across CEE, CIS and Central Asia. Highly comparable in product breadth (generics across multiple therapeutic areas) and geographic emphasis, but at materially larger scale and with deeper EU/US regulatory dossiers.
• Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical company with significant operations across MENA, Europe and emerging markets. Comparable in its generics-driven export model targeting non-Western European markets and its focus on therapeutic breadth across cardiovascular and anti-infective categories.

Regional players

• Hemofarm: Serbian pharmaceutical manufacturer (now part of STADA group) producing generics across multiple therapeutic areas with strong Balkan and CIS presence. Comparable in its integrated solid-dosage manufacturing and regional export model, though with larger EU footprint via its parent.
• Alkaloid: North Macedonia-based pharmaceutical manufacturer producing generics, OTC products and cosmetics for regional markets. Comparable in its solid-dosage manufacturing focus and CEE/CIS geographic emphasis, though it is more advanced in EU regulatory penetration.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@gmpharma7987
• Facebookfacebook.com/gmpharma.ge
• LinkedInlinkedin.com/company/gmpharmaceuticals
• Instagraminstagram.com/gmpharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GM PHARMA